Equity Profile

EWTX

Edgewise Therapeutics, Inc.

Health CarePharmaceuticals$4.7B

Aug6Thu

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EDT

Company Snapshot

Edgewise Therapeutics, Inc. is a pharmaceutical company focused on developing innovative therapies for rare diseases....

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability, and investors will be keen to see if the company can narrow its losses.

N/A

Revenue

Although specific revenue estimates are not available, any revenue growth would signal progress in their drug development efforts.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

EWTX Q2-2026 Earnings Preview

Context

Company Snapshot

Edgewise Therapeutics, Inc. is a pharmaceutical company focused on developing innovative therapies for rare diseases. Operating in the health care sector, its work is crucial as it aims to address unmet medical needs, particularly in the treatment of muscle disorders.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

75%

Avg EPS Surprise

+3.24%

Avg Stock Reaction

-1.70%

Last Quarter Recap

In Q1-2026, Edgewise reported an EPS of -$0.46, which was better than the expected -$0.50, marking an 8.18% surprise. However, the stock fell 3.81% the following day, indicating investor caution despite the positive surprise.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall, expectations for Edgewise's upcoming earnings are mixed, given the company's history of beating EPS estimates but not necessarily translating that into positive stock movement.

Bull Case

If Edgewise can continue its trend of beating EPS estimates, it may signal strong underlying business performance and investor confidence.

Bear Case

Conversely, if the company fails to meet expectations again, it could raise concerns about its growth prospects and lead to further declines in stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will the EPS for Q2-2026 show a continued improvement compared to prior quarters?

Given the company's recent history of beating EPS estimates, this will be a critical measure of its financial health and operational efficiency.

What updates will management provide on drug development timelines and potential revenue streams?

Investors will be looking for clarity on the company's pipeline, as successful drug development is essential for future revenue growth.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate the potential for Edgewise to significantly narrow its losses this quarter, as recent operational improvements are not fully reflected in current expectations.

Supporting Evidence

The company has a strong track record of beating EPS estimates, which could indicate better-than-expected performance.

The options market is pricing in a larger move than historical averages, suggesting that traders anticipate significant news.

Key Risk

If EPS comes in better than -$0.40, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate this quarter revolves around whether Edgewise can demonstrate improved financial performance and progress in its drug development pipeline.

Bull Confirmed If

A narrower EPS loss of less than -$0.40 would confirm the bullish case.

Bear Confirmed If

An EPS loss greater than -$0.50 would support the bearish case.

Pre-Earnings Positioning

Options Market

Implied Move

±4.5%

Historical Avg

±2.5%

Pricing rich

The options market is pricing in a significant move, suggesting that traders expect volatility around the earnings announcement.

Options are pricing ±4.5% while EWTX has averaged ±2.5% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.9%

30d HV

67.4%

Calls (3K)P/C Ratio: 0.10Puts (800)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Edgewise beats expectations, history suggests the stock could see an average one-day move of +2.9%, confirming positive investor sentiment.

In-Line / Cautious

If results are in line with expectations, the stock may experience muted movement as investors await further clarity from management.

Miss

A miss could lead to a decline, with history suggesting an average one-day move of -1.99%, reflecting investor disappointment.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on the timelines for drug trials and potential approvals.
2Details on cost management and operational efficiencies.
3Insights into market demand for their therapies.
4Management's outlook on future revenue streams.
5Responses to any competitive developments in the pharmaceutical space.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug3

ONBMO

ON Semiconductor Corporation

PreviewView

Aug3

LBMO

Company Snapshot

Edgewise Therapeutics, Inc. is a pharmaceutical company focused on developing innovative therapies for rare diseases....

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability, and investors will be keen to see if the company can narrow its losses.

N/A

Revenue

Although specific revenue estimates are not available, any revenue growth would signal progress in their drug development efforts.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

EWTX Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

75%

Avg EPS Surprise

+3.24%

Avg Stock Reaction

-1.70%

Last Quarter Recap

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall, expectations for Edgewise's upcoming earnings are mixed, given the company's history of beating EPS estimates but not necessarily translating that into positive stock movement.

Bull Case

If Edgewise can continue its trend of beating EPS estimates, it may signal strong underlying business performance and investor confidence.

Bear Case

Conversely, if the company fails to meet expectations again, it could raise concerns about its growth prospects and lead to further declines in stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will the EPS for Q2-2026 show a continued improvement compared to prior quarters?

Given the company's recent history of beating EPS estimates, this will be a critical measure of its financial health and operational efficiency.

What updates will management provide on drug development timelines and potential revenue streams?

Investors will be looking for clarity on the company's pipeline, as successful drug development is essential for future revenue growth.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate the potential for Edgewise to significantly narrow its losses this quarter, as recent operational improvements are not fully reflected in current expectations.

Supporting Evidence

The company has a strong track record of beating EPS estimates, which could indicate better-than-expected performance.

The options market is pricing in a larger move than historical averages, suggesting that traders anticipate significant news.

Key Risk

If EPS comes in better than -$0.40, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate this quarter revolves around whether Edgewise can demonstrate improved financial performance and progress in its drug development pipeline.

Bull Confirmed If

A narrower EPS loss of less than -$0.40 would confirm the bullish case.

Bear Confirmed If

An EPS loss greater than -$0.50 would support the bearish case.

Pre-Earnings Positioning

Options Market

Implied Move

±4.5%

Historical Avg

±2.5%

Pricing rich

The options market is pricing in a significant move, suggesting that traders expect volatility around the earnings announcement.

Options are pricing ±4.5% while EWTX has averaged ±2.5% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.9%

30d HV

67.4%

Calls (3K)P/C Ratio: 0.10Puts (800)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Edgewise beats expectations, history suggests the stock could see an average one-day move of +2.9%, confirming positive investor sentiment.

In-Line / Cautious

If results are in line with expectations, the stock may experience muted movement as investors await further clarity from management.

Miss

A miss could lead to a decline, with history suggesting an average one-day move of -1.99%, reflecting investor disappointment.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on the timelines for drug trials and potential approvals.
2Details on cost management and operational efficiencies.
3Insights into market demand for their therapies.
4Management's outlook on future revenue streams.
5Responses to any competitive developments in the pharmaceutical space.